

Omaha Public Power District
444 South 16th Street Mall
Omaha, Nebraska 68102-2247
402/636-2000

February 13, 1991
LIC-91-069R

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Mail Station P1-137
Washington, DC 20555

References: Docket No. 50-285

Gentlemen:

SUBJECT: Report of Unsatisfactory Performance Testing

Pursuant to 10 CFR 26, Appendix A, Subpart B, Section 2.8(e)(4), please find attached a report of an unsatisfactory performance testing incident. The incident was reported to Omaha Public Power District (OPPD) on January 17, 1991, by the OPPD Medical Review Officer with respect to testing which was conducted on December 13, 1990.

If you should have any questions, please contact me.

Sincerely,

W. G. Gates

W. G. Gates
Division Manager
Nuclear Operations

WGG/sel

Attachment

c: LeBoeuf, Lamb, Leiby & MacRae
R. D. Martin, NRC Regional Administrator, Region IV
W. C. Walker, NRC Project Manager

9102200284 910213
PDR ADOCK 05000285
PDR



January 18, 1991

Mr. Robert Guy
Manager-Labor Relations
Omaha Public Power District
444 South 16 Street Mall
Omaha, Nebraska 68102-2247

Re: Drug Screening Sample #SCM092460

Dear Mr. Guy:

This report is a follow-up to our conversation of January 17 regarding the drug screen on #SCM092460. As I indicated by telephone, the problem with the initial drug screen was addressed and I feel confident it has been corrected.

Drug screen #SCM092460 underwent a random drug screen on December 13, 1990. On the 17th of December we received a report of amphetamines in significant quantities of 645 ng./ml. Because we had not previously received any previous reports of positive amphetamines and because the donor was taking an Ephedrine-like compound, I requested a recheck of the urine and second confirmation by CompuChem.

On December 20 of 1990 a report was received from CompuChem indicating again not only the presence of amphetamines in a concentration of 682 ng./ml., but also methamphetamine in a concentration of 1264 mg./ml. The methamphetamine had not been reported on the initial drug screen.

The drug screen was reviewed with the donor on the 20th of December by Dr. Dean Wampler. He was pronounced not fit for duty on that date.

Because of the failure to report methamphetamine on the initial report, we have requested further information from CompuChem regarding this discrepancy. I am enclosing a copy of a letter from Dr. Michael Peat regarding this testing and after receiving this letter a phone call was placed to Dr. Peat on the 16th of January. Dr. Peat apparently was out of town on that date but on the 17th of January I received a phone call from one of the laboratory personnel regarding the problems that led up to this discrepancy. Essentially his verbal report confirmed the written report extended by Dr. Peat.

Allergy & Immunology
Cardiology
Dermatology
Ears, Nose & Throat
Family Practice
Gastroenterology
Hematology-Oncology
Internal Medicine
Medical Psychology
Obstetrics & Gynecology
Occupational Medicine
Ophthalmology
Orthopedic Surgery
Pediatrics
Physical Therapy
Plastic, Reconstructive
& Hand Surgery
Surgery-General
Urology

10060 Regency Circle
Omaha, NE 68114
402/397-4000

3908 S. 142nd Street
Millard, NE 68137
402/895-4490

14625 California
Omaha, NE 68154
402/496-0610

Mr. Robert Guy
Manager-Labor Relations
Omaha Public Power District
Page 2

I feel confident that CompuChem has addressed this problem appropriately. I also feel that, at no time was the Fitness-for-Duty program jeopardized in any way by this report since amphetamines were found in the urine and the employee was removed from duty in an appropriate and timely manner. The problem remains, however, that there was an error in reporting a drug screen which in essence is a partial false-negative report. Again, in no way did this jeopardize the Fitness-for-Duty program, but I felt that follow-up and report of this incident should be carried out.

Sincerely,

Ronald W. Olmhausen

Ronald W. Olmhausen, M.D.
Medical Director
Physicians Clinic
(402) 390-1352

RWO/vmt

Enclosure



COMPUCHEM
LABORATORIES, INC.

P.O. Box 12652 3308 Chapel Hill/Neilson Highway Research Triangle Park, NC 27709 (919) 549-8263

January 10, 1991

To: Dr. Olnhausen
Physicians Clinic
10060 Regency Circle
Omaha
NE 68114
12-11-90
RE: SCM092460, CCNS32081416 and 30525828

Dear Dr. Olnhausen:


The above referenced sample was received on December 13, 1990 and reported to you on December 17, 1990 as positive amphetamine. On December 18, 1990 you requested a retest for amphetamines by GCMS, the results of this test were reported to you as positive methamphetamine and amphetamine.

The reason for the discrepancy was a failure by our data review staff to interpret the GC-MS chromatographic traces correctly. The tracing for methamphetamine from the original test is attached to this letter. The three items of interest are the squares labelled in the bottom left corner 255, 210 and 254 as these represent methamphetamine. Each of these squares contain two peaks, one large one at 4.74/4.75 and one smaller one at 4.61 which is methamphetamine. The software integration failed to detect this smaller peak and therefore reported the result as negative. However the data reviewer should have caught this error and requested that the GC-MS data be reprocessed. For your interest the peak at 4.75 represents the active constituent of Primatene.

To avoid a reoccurrence of this error GC-MS operators and data reviewers have been counseled and have been instructed to ensure that such peaks are reprocessed. We are also in the process of changing our software to ensure that it selects the correct peak rather than the largest peak.

I trust that this explanation is satisfactory but if further information is required please call me at 919-248-6810.

Yours sincerely,

A handwritten signature in cursive script, appearing to read "Michael A. Peat". The signature is written in dark ink and is positioned above the typed name. A long horizontal line is drawn across the signature, extending to the right.

Michael A. Peat Ph.D.
Vice President of Toxicology

cc: Ms. Kathleen Flaherty

CompuChem Laboratories
 Forensic Drug Testing
 Methamphetamine Confirmation by GC/MSD


Sample Name = 32081416 ALS Bottle No. = 19
 DataFile = >11DT6:UX Operator = 975
 Time of Injection = 12/14/90 17:37
 Retention Time = 4.59 D5-MAP | <OUT> +/-2% = 4.51 - 4.69
 Retention Time = 4.74 MAP | <OUT> +/-2% = 4.51 - 4.70
 Misc. info = 034251 I#27 P=*AMP ST=AMP OP#975 14 Dec 90 5:37 pm
 ----- ION PEAK AREAS and RATIOS -----

MAP => 254 = 7944330 210 = 132664 255 = 2261291
 D5-MAP => 258 = 158905 120 = 16276 213 = 48295

MAP => 210/254 = 0.02 <OUT> +/- 20% = 0.37 - 0.56
 255/254 = 0.28 <OUT> +/- 20% = 0.09 - 0.14
 D5-MAP => 120/258 = 0.10 +/- 20% = 0.08 - 0.12
 213/258 = 0.30 +/- 20% = 0.24 - 0.36

MAP / D5-MAP => 254/258 = 49.99 ***QUANT RATIO

Drug Not Identified => Concentration = 0.00 ng/ml
 Time Stamp of Last Calibration = <901214.0201>



COMPU-CHEM
 LABORATORIES